BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 24114022)

  • 21. Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer.
    Yasue M; Sakamoto J; Teramukai S; Morimoto T; Yasui K; Kuno N; Kurimoto K; Ohashi Y
    Pancreas; 1994 Nov; 9(6):735-40. PubMed ID: 7846017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
    Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
    Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer.
    Ychou M; Duffour J; Kramar A; Gourgou S; Grenier J
    Dis Markers; 2000; 16(3-4):105-10. PubMed ID: 11381189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive Early Recurrence Factors of Preoperative Clinicophysiological Findings in Pancreatic Cancer.
    Suzuki S; Shimoda M; Shimazaki J; Maruyama T; Oshiro Y; Nishida K; Sahara Y; Nagakawa Y; Tsuchida A
    Eur Surg Res; 2018; 59(5-6):329-338. PubMed ID: 30453288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.
    Feng F; Tian Y; Xu G; Liu Z; Liu S; Zheng G; Guo M; Lian X; Fan D; Zhang H
    BMC Cancer; 2017 Nov; 17(1):737. PubMed ID: 29121872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ABO blood type, smoking status, other risk factors and prognosis of pancreatic ductal adenocarcinoma.
    Li SS; Zhou CY; Liao R; Xiong L; Weng NN; Zhao YQ; Mason C; Gou HF; Yi C; Zhu Q
    Medicine (Baltimore); 2020 Apr; 99(14):e19413. PubMed ID: 32243360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic and predictive value of serum CA19.9 in pancreatic cancer.
    Humphris JL; Chang DK; Johns AL; Scarlett CJ; Pajic M; Jones MD; Colvin EK; Nagrial A; Chin VT; Chantrill LA; Samra JS; Gill AJ; Kench JG; Merrett ND; Das A; Musgrove EA; Sutherland RL; Biankin AV;
    Ann Oncol; 2012 Jul; 23(7):1713-22. PubMed ID: 22241899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer.
    Ishigami S; Natsugoe S; Hokita S; Che X; Tokuda K; Nakajo A; Iwashige H; Tokushige M; Watanabe T; Takao S; Aikou T
    J Clin Gastroenterol; 2001 Jan; 32(1):41-4. PubMed ID: 11154168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer.
    Liang Y; Wang W; Fang C; Raj SS; Hu WM; Li QW; Zhou ZW
    Oncotarget; 2016 Aug; 7(31):49565-49573. PubMed ID: 27385101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer.
    Reitz D; Gerger A; Seidel J; Kornprat P; Samonigg H; Stotz M; Szkandera J; Pichler M
    J Clin Pathol; 2015 Jun; 68(6):427-33. PubMed ID: 25759406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer.
    Liu L; Xu H; Wang W; Wu C; Chen Y; Yang J; Cen P; Xu J; Liu C; Long J; Guha S; Fu D; Ni Q; Jatoi A; Chari S; McCleary-Wheeler AL; Fernandez-Zapico ME; Li M; Yu X
    Int J Cancer; 2015 May; 136(9):2216-27. PubMed ID: 25273947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer.
    Sakamoto T; Saito H; Amisaki M; Tokuyasu N; Honjo S; Fujiwara Y
    Hepatobiliary Pancreat Dis Int; 2019 Jun; 18(3):278-284. PubMed ID: 30987900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
    Chen T; Zhang MG; Yu XJ; Liu L
    Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
    Yang XQ; Chen C; Wang FB; Peng CW; Li Y
    Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma.
    Tokunaga R; Imamura Y; Nakamura K; Uchihara T; Ishimoto T; Nakagawa S; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Oyama S; Shono T; Naoe H; Saeki H; Oki E; Watanabe M; Sasaki Y; Maehara Y; Baba H
    Cancer Med; 2015 Nov; 4(11):1659-66. PubMed ID: 26310928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative serum carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer.
    Yang XQ; Li Y; Chen C; Peng CW; Liu SP; Liu Y
    Med Oncol; 2011 Sep; 28(3):789-95. PubMed ID: 20373053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic and prognostic values of anti-helicobacter pylori antibody combined with serum CA724, CA19-9, and CEA for young patients with early gastric cancer.
    Gong X; Zhang H
    J Clin Lab Anal; 2020 Jul; 34(7):e23268. PubMed ID: 32118318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The diagnostic role of the neutrophil-to-lymphocyte ratio in predicting pancreatic ductal adenocarcinoma in patients with pancreatic diseases.
    Arima K; Okabe H; Hashimoto D; Chikamoto A; Tsuji A; Yamamura K; Kitano Y; Inoue R; Kaida T; Higashi T; Taki K; Imai K; Komohara Y; Beppu T; Takeya M; Baba H
    Int J Clin Oncol; 2016 Oct; 21(5):940-945. PubMed ID: 27023215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Prognostic Relevance of Preoperative CEA and CA19-9 for Ampulla of Vater Carcinoma.
    Matsui S; Yamamoto Y; Okamura Y; Ito T; Ashida R; Ohgi K; Yamada M; Otsuka S; Uesaka K; Sugiura T
    Anticancer Res; 2022 Jun; 42(6):3169-3176. PubMed ID: 35641260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.
    Joergensen MT; Brünner N; De Muckadell OB
    Anticancer Res; 2010 Feb; 30(2):587-92. PubMed ID: 20332475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.